Skip to content

Study · Not a test of the peptide alone · 1996

3 results

Design and characterisation of long-R3-insulin-like growth factor-I muteins which show resistance to pepsin digestion.

Bryant KJ, Read LC, Forsberg G, Wallace JC

Growth factors (Chur, Switzerland)1 Jan 1996Cited by 4 (Europe PMC)

PMID8919033 (opens in a new tab)DOI10.3109/08977199609003227 (opens in a new tab)PepBankPUB-08919033
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 LR3.

  1. 01LabNot a test of IGF-1 LR3 aloneIn vitro (cell-free)Other

    Purified porcine pepsin first cleaved the Leu10-Phe11 bond in the N-terminal extension of long-R3-IGF-I, then four further bonds.

    In plain wordsIn lab tests, pepsin cut long-R3-IGF-I first in its added N-terminal tail, then at four more sites.

    Peptide
    IGF-1 LR3
    Outcome
    Not applicablePepsin cleavage sites of long-R3-IGF-I
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Pepsin initially cleaved the Leu10-Phe11 bond in the N-terminal extension peptide to generate FVN-R3-IGF-I, followed in rapid succession by cleavage at Gln15-Phe16, Tyr24-Phe25, Leu10-Val11 and Met59-Tyr60 in the IGF-I moiety.
    1 context sentence
    Summary · context
    Site-directed mutagenesis was used to construct pepsin-resistant, single-point mutations of the N-terminal extended IGF-I analogue, long-R3-IGF-I.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

  2. 02LabNot a test of IGF-1 LR3 aloneIn vitro (cell-free)Other

    Leu10Val and Asp53Glu muteins were degraded by pepsin as rapidly as parent long-R3-IGF-I, Met59Gln and Phe25Leu were partially stabilised, and Phe16Ala was markedly more stable.

    In plain wordsIn lab tests, one altered form of long-R3-IGF-I, Phe16Ala, resisted pepsin much better than the parent peptide. Others resisted less or not at all.

    Peptide
    IGF-1 LR3
    Outcome
    MixedPepsin stability of long-R3-IGF-I muteins
    Study

    n: not reported in source

    Comparator
    Parent long-R3-IGF-I
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    In terms of pepsin susceptibility, Leu10Val and Asp53Glu were degraded as rapidly as the parent long-R3-IGF-I, Met59Gln and Phe25Leu were partially stabilised, and Phe16Ala showed a marked improvement in stability over a wide range of pepsin:substrate ratios.
    1 context sentence
    Summary · context
    Site-directed mutagenesis was used to construct pepsin-resistant, single-point mutations of the N-terminal extended IGF-I analogue, long-R3-IGF-I.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

  3. 03LabNot a test of IGF-1 LR3 aloneOther designActivity measurement

    All five long-R3-IGF-I muteins kept growth-promoting activity equivalent to or higher than that of IGF-I.

    In plain wordsIn lab tests, five altered forms of long-R3-IGF-I kept growth-promoting activity equal to or higher than IGF-I.

    Peptide
    IGF-1 LR3
    Outcome
    MixedGrowth-promoting activity of five pepsin-resistant long-R3-IGF-I muteins
    Study

    n: not reported in source

    Comparator
    IGF-I
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    All five muteins retained growth-promoting activity equivalent to or higher than that of IGF-I.
    1 context sentence
    Summary · context
    Site-directed mutagenesis was used to construct pepsin-resistant, single-point mutations of the N-terminal extended IGF-I analogue, long-R3-IGF-I.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.